Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Research and Innovation Action · Running

ONCOSCREEN A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways

Coordinator
Exus Software Monoprosopi Etairia Periorismenis Evthinis, Greece
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€13.0m
Total cost
€13.0m
Partners
43 organisations in 16 countries
Type
Research and Innovation Action
Grant agreement
101097036

What the project is doing

In the project's own words, from its summary on CORDIS.

With Colorectal Cancer (CRC) being accountable for 12.4% of all deaths due to cancer, and with only 14% of EU citizens participating in screening programmes, there is an urgent need for accurate, non-invasive, cost-effective screening tests based on novel technologies and an increased awareness on the disease and its detection. Furthermore, personalized approaches for screening are needed, to consider genetic and other socioeconomic variables and environmental stressors that lead to different onsets of the disease.

ONCOSCREEN responds to these challenges by developing a risk-based, population-level stratification methodology for CRC, to account for genetic prevalence, socio-economic status, and other factors. It complements this methodology by a) developing a set of novel, practical, and low-cost screening technologies with high sensitivity and specificity, b) leveraging AI to improve existing methodologies for CRC screening, allowing for the early detection of polyps and provision of a personalized risk status stratification, and c) providing a mobile app for self-monitoring and CRC awareness raising.

Furthermore, ONCOSCREEN develops an Intelligent Analytics dashboard for policy makers facilitating effective policy making at regional and national levels. Through a multi-level campaign, the above-mentioned solutions are tested and validated. For the clinical solutions specifically, a clinical validation study has been planned with the participation of 4100 enrolled patients/citizens. To ensure the adoption of the developed solutions by the healthcare systems, their cost-effectiveness and financial viability will be assessed.

The 48-months duration project will be implemented by a multidisciplinary consortium comprising of 38 partners, including technical solutions providers, hospitals, Ministries of Health as policy makers, legal and ethics experts, Insurance companies, involving actively end-users/citizens in all phases of implementation through targeted workshops. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.

Topics

Who is involved

OrganisationCityCountryRole
Exus Software Monoprosopi Etairia Periorismenis EvthinisAthinaGreeceCoordinator
Europaische Vereinigung Der Gastrointestinalen Onkologie(european Society of Digestive Oncology - Esdo)WienAustriaParticipant
Medizinische Universitat GrazGrazAustriaParticipant
Medizinische Universitat InnsbruckInnsbruckAustriaParticipant
Ainigma TechnologiesLeuvenBelgiumParticipant
Innovation SprintBruxelles / BrusselBelgiumParticipant
TimelexBruxelles / BrusselBelgiumParticipant
Vlaamse Instelling Voor Technologisch Onderzoek N.v.MolBelgiumParticipant
Rosenbaum ConsultingSofiaBulgariaParticipant
Catalink LimitedNicosiaCyprusParticipant
Scientific Academy for Service Technology eVPotsdamGermanyParticipant
Universitaet Zu LuebeckLubeckGermanyThird party
Universitaetsmedizin Der Johannes Gutenberg-Universitaet MainzMainzGermanyParticipant
Universitatsklinikum Schleswig-HolsteinLübeckGermanyParticipant
Elliniki Etaireia Ogkologias PeptikouChaidari AthinaGreeceParticipant
Erevnitiko Panepistimiako Institouto Systimaton Epikoinonion Kai YpologistonAthinaGreeceParticipant
Ethniko Kentro Erevnas Kai Technologikis AnaptyxisThermi ThessalonikiGreeceParticipant
Geniko Nosokomeio Elena Venizelou -AlexandraAthinaGreeceParticipant
Ypourgeio YgeiasAthinaGreeceParticipant
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Universidad De La RiojaLogronoSpainParticipant
Association GercorParisFranceParticipant
FiralisHuningueFranceParticipant
Gie AxaParisFranceParticipant
Universite Marie Et Louis PasteurBesanconFranceParticipant
Carr Communications LimitedDublinIrelandParticipant
Konnekt Able Technologies LimitedDundalk Co LouthIrelandParticipant
Technion - Israel Institute of TechnologyHaifaIsraelParticipant
Ey Advisory SpAMilanoItalyParticipant
Lietuvos Respublikos Sveikatos Apsaugos MinisterijaVilniusLithuaniaParticipant
Lietuvos Sveikatos Mokslu UniversitetasKaunasLithuaniaParticipant
Pagalbos Onkologiniams Ligoniams AsociacijaKaunasLithuaniaParticipant
Louwen RogierOosterhoutNetherlandsParticipant
Tilburg University- Universiteit Van TilburgTilburgNetherlandsParticipant
Voogd SanneRoosendaalNetherlandsParticipant
Europacolon Portugal- Associacao De Luta Contra O Cancro Do IntestinoPortoPortugalParticipant
Instituto Portugues De Oncologia Do Porto Francisco Gentil, EpePortoPortugalParticipant
Universidade Do MinhoBragaPortugalParticipant
Beia Consult International SRLBucurestiRomaniaParticipant
Delta Health Care S.R.LBucharest - District 1RomaniaParticipant
Fundatia Youth Cancer EuropeCluj NapocaRomaniaParticipant
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu BucurestiBucharestRomaniaParticipant
Fakultna Nemocnica S Poliklinikou F.d. Roosevelta Banska BystricaBanska BystricaSlovakiaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI